Skip to main content
TipRanks
Go Ultimate75% OFF

Zura Bio (94E) AI Stock Analysis

3 Followers
DE:94E

Zura Bio

(Frankfurt:94E)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-Free Balance SheetA zero-debt capital structure reduces near-term solvency and refinancing pressure while preserving flexibility to fund clinical development. Positive equity provides an additional financial buffer, although continued losses could gradually erode this strength if operating performance does not improve.
Negative Factors
No Commercial RevenueZura has not yet demonstrated commercial revenue to offset research and corporate spending, while its TTM loss widened materially from 2025. This pre-revenue model leaves near-term financial performance dependent on clinical progress rather than an established earnings base.

Zura Bio (94E) vs. iShares MSCI Germany ETF (EWG)

-75%-50%-25%0%25%50%75%100%DE:94E-66.67%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 119.44M
Dividend Yield
―
Average Volume (3M)
810
Price to Earnings (P/E)
-1.1
Beta (1Y)
0.91
Revenue Growth
―
EPS Growth
-68.00%
Country
Germany
Employees
40
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Zura Bio Business Overview & Revenue Model

Company Description

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα...

Zura Bio Risk Analysis

Zura Bio disclosed 82 risk factors in its most recent earnings report. Zura Bio reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Zura Bio Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:94E against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PBYIPBYI64Neutral$401.70M16.3217.52%―9.35%-37.15%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
VORVOR45Neutral$1.19B0.06-830.38%―――
CLLSCLLS44Neutral$84.18M-1.78-94.14%―-0.11%-13.99%
PRQRPRQR42Neutral$198.98M-3.23-68.44%―19.49%-4.53%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%DE:94EPBYIPRQRCLLSVORDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:94E and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:94EZura Bio Limited1.12-2.38-68.00%
PBYIPuma Biotechnology7.772.8156.65%
PRQRProQR Therapeutics BV1.41-0.64-31.22%
CLLSCellectis S.A.1.18-2.96-71.50%
VORVor Biopharma, Inc.19.429.4093.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.